Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Lee, Dasom ^{[1
]}

Kambhampati, Swetha ^{[2
]}

Bobillo, Maria Silvina Odstrcil ^{[3
]}

Adedokun, Babatunde ^{[4
]}

Shadman, Mazyar ^{[5
,6
]}

Olson, Amanda L. ^{[7
]}

Herrera, Alex F. ^{[8
]}

Lee, Catherine J. ^{[5
,6
]}

Jacobson, Caron A. ^{[9
]}

Bye, Matthew ^{[10
]}

Hamadani, Mehdi ^{[10
]}

Kim, Soyoung ^{[11
]}

Dahiya, Saurabh ^{[12
]}

Hu, Zhen-Huan ^{[4
]}

Speth, Kelly ^{[4
]}

To, Christina ^{[4
]}

Mirjah, Debbie L. ^{[13
]}

Best, Timothy ^{[4
]}

Locke, Frederick L. ^{[14
]}

Ahmed, Nausheen ^{[15
]}

Tees, Michael T. ^{[16
]}

Pasquini, Marcelo C. ^{[17
]}

Ahmed, Sairah ^{[18
]}

机构：

[1] Stanford Univ, Div Hematol, Palo Alto, CA USA

[2] City Hope Natl Med Ctr, Yorba Linda, CA USA

[3] Univ Utah, Salt Lake City, UT USA

[4] Kite A Gilead Co, Santa Monica, CA USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Med Oncol Div, Seattle, WA USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI USA

[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Registry CIBMTR, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA

[12] Stanford Univ, Div Hematol, Stanford, CA USA

[13] Gilead Co, Santa Monica, CA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplant & Cellular Immunotherapy, Tampa, FL USA

[15] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA

[16] Sarah Cannon transplant & Cellular Therapy Network, Nashville, TN USA

[17] Dana Farber Canc Inst, Boston, MA USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：527 / 528

页数：2

共 50 条

[1] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[2] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Khurana, Arushi
Bailey, Megumi
Iqbal, Madiha
Bansal, Radhika
Lee, Catherine J.
Hunter, Bradley
Lunning, Matthew A.
Jaglowski, Samantha
Jain, Michael D.
Dahiya, Saurabh
Bachanova, Veronika
Farooq, Umar
Ahmed, Sairah
Hill, Brian T.
Munoz, Javier L.
Patel, Krish
Oluwole, Olalekan O.
Lin, Yi
BLOOD, 2022, 140 : 4657 - 4660
[3] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Houot, Roch
Minnema, Monique
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
[4] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Topp, Max S.
van Meerten, Tom
Wermke, Martin
Lugtenburg, Elly J.
Minnema, Monique C.
Song, Kevin W.
Thieblemont, Catherine
Jiang, Yizhou
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Cook, Michael Roderick
Shouval, Roni
Perales, Miguel-Angel
Bezerra, Evandro
Niu, Alex
Dahiya, Saurabh
Nastoupil, Loretta J.
Jacobson, Caron A.
Budde, L. Elizabeth
Olson, Amanda L.
Logan, Brent R.
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Kim, Jenny J.
Smith, Harry W.
Lee, Andrew
Sun, Fang
Pasquini, Marcelo
Locke, Frederick L.
BLOOD, 2023, 142
[6] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
Hathway, Joanne
Purdum, Anna
Lin, Vincent W.
Cyr, Philip
Westin, Jason
Jensen, Ivar
BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
[8] Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
Locke, Frederick L.
Siddiqi, Tanya
Jacobson, Caron Alyce
Ghobadi, Armin
Ahmed, Sairah
Miklos, David Bernard
Perales, Miguel-Angel
Munoz, Javier
Logan, Brent
Hu, Zhen-Huan
Miao, Harry H.
Singh, Kanwarjit
Shah, Jina
Xu, Hairong
Pasquini, Marcelo C.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
Ball, G.
Kuruvilla, J.
Boodoo, C.
Jain, M. D.
VALUE IN HEALTH, 2021, 24 : S39 - S39
[10] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
Diakite, I
Lin, V. W.
Klijn, S.
Navale, L.
Purdum, A. G.
Fenwick, E.
Botteman, M.
van Hout, B.
VALUE IN HEALTH, 2019, 22 : S41 - S41

← 1 2 3 4 5 →